BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Siegfried Release: Profitability Further Enhanced -- Basis Set for Continued Growth


8/30/2012 10:52:18 AM

Zofingen, August 30, 2012 -- During the first half of 2012 the Siegfried Group (SIX: SFZN) successfully maintained revenue growth and increased profitability while progressing with the company strategy. Net sales increased by 2.9% (3.3% in local currencies) over 2011, to CHF 178.7 million. Sales of Drug Products rose markedly after the launch of new drugs in the first half year. The impact on revenue growth of the entire company was only partial since in Drug Substance business lower costs for raw materials were passed on to customers. That led to a dispropor- tionate increase of earnings before interest, taxes, depreciation and amortization (EBITDA) by 32.3% to CHF 21.3 million, corresponding to a 12% margin. The company is optimistic that the current positive trend will continue through the second half of the year.

Growth was 2.1% when adjusted for the AMP acquisition. EBIT grew by 113% to CHF 9.0 million and a 5.1% margin. Net profit for the first half of the year was CHF 13.2 million, 7.4% of net sales.

Continued robust cash situation – impact of FX moderate

The company’s net debt after the acquisition of Alliance Medical Products, Inc. at the end of the first six months was CHF 2.4 million (excl. financial assets), which is still a robust financial situation. The negative foreign currency effect of CHF 0.6 million on operating results for the first half of 2012 remained moderate. The company maintains a ‘natural hedge’ (a combination of US dollars and Euros) of just over 80%

AMP strengthens technology base

The acquisition of Alliance Medical Products, Inc. (AMP) in Irvine, California is a further step in Siegfried’s overall corporate strategy. AMP strengthens the company’s competencies in the area of pharmaceutical production / sterile fillings and ads to Siegfried’s USP of offering comprehensive know-how in both chemical and pharmaceutical production. AMP represents not only a technology win but also complements the Siegfried company culture very well. In addition, Siegfried can open the European market to AMP, which was previously active only in the U.S.A. Discussions are now being held with Siegfried clients.

New suite for high potency drugs starts up in Zofingen

In the first half of 2012, a new suite for the development of high potency drugs was set up and began operation after authorization by Swissmedic, the Swiss regulatory agency. This enhancement also positions Zofingen to offer know-how for both chemical and phar- maceutical production of highly active ingredients – being our USP.

Production facility planned for China

Siegfried plans to further improve its competitiveness with a new production facility in the modern Nantong Industrial Park northwest of Shanghai, China. In an initial phase, Siegfried is investing in the construction of a production facility for active pharmaceutical ingre- dients and intermediates. The available property will also allow expansion in a second phase and the possibility of adding a production line for finished drug products.

The Nantong Industrial Park features many well-known companies. The location has numerous advantages. Our partner, NETDA (Nan- tong Economic & Technological Development Area) will provide a fully-functional industrial park infrastructure. Production start is set for 2014.

Continuing a positive trend

Barring unexpected developments, such as volatility in the currency and raw materials markets, the Siegfried Group expects the current positive trend to continue. The company anticipates growth rates in the high single-digit for the rest of the year (including the contri- bution from AMP) and an EBITDA margin consistent with the first half of 2012.

For further information:

Michael Huesler, Chief Financial Officer

michael.huesler@siegfried.ch

Phone: +41 (0)62 746 11 35

Fax +41 (0)62 746 11 03

Siegfried Holding AG

Untere Brühlstrasse 4

CH-4800 Zofingen, Switzerland

Phone +41 (0)62 746 11 11

Fax +41 (0)62 746 11 03

www.siegfried.ch



Read at BioSpace.com

Siegfried
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->